EDSA Stock Soars More Than 700% So Far This Year: Wall Street Eyes Further Upside In Run Up To Acute Kidney Injury Data Reveal

• Edesa said it will deliver an oral presentation at the 63rd European Renal Association (ERA) Congress, scheduled for June 3–6 in Glasgow, Scotland.
• At the upcoming conference, Edesa will present data drawn from its late-stage study in patients with respiratory distress who also developed acute kidney injury.
• The Toronto-based clinical-stage biopharmaceutical company, which remains pre-revenue, ended its March quarter with $10.0 million in cash and cash equivalents and $8.2 million in working capital.

Edesa Biotech (EDSA) shares rallied as much as 34% on Tuesday, snapping a three-day streak of closing in the red, after the clinical-stage company announced it will present new exploratory data on its lead candidate, paridiprubart, for acute kidney injury at a major European nephrology conference.

Edesa said it will deliver an oral presentation at the 63rd European Renal Association (ERA) Congress, scheduled for June 3–6 in Glasgow, Scotland. The talk is set for June 5 at 4:30 p.m. local time.

EDSA stock has gained 506% over the past 12 months. However, according to data from Koyfin, the sole analyst covering EDSA rates it a ‘Buy’ with a $14 price target, representing a further potential upside of 56% from the last closing price.

Upcoming Presentation

At the upcoming conference, Edesa will present data drawn from its late-stage study in patients with respiratory distress who also developed acute kidney injury, a common, high-mortality complication. Acute kidney injury affects an estimated 13 million people worldwide each year and currently has no approved targeted pharmacological therapies.

“The ERA Congress represents a critical platform to advance awareness of paridiprubart’s potential in AKI—a disease with profound unmet need and limited therapeutic options,” said Par Nijhawan, CEO of Edesa Biotech. “Our Phase 3 data demonstrate a consistent, statistically significant reduction in mortality in AKI patients, grounded in a well-established mechanism.”

EDSA’s Financials

Last week, Edesa reported fiscal second-quarter 2026 results for the period ended March 31, posting a net loss of $4.2 million, or $0.49 per share, compared with a $1.6 million loss, or $0.30 per share, in the year-ago quarter. Total operating expenses rose sharply to $4.3 million from $1.6 million, driven largely by a $2.3 million increase in research and development spending tied to manufacturing and clinical preparations for its EB06 vitiligo program and regulatory and manufacturing readiness activities for paridiprubart. The Toronto-based clinical-stage biopharmaceutical company, which remains pre-revenue, ended the quarter with $10.0 million in cash and cash equivalents and $8.2 million in working capital.

What Do Retail Traders Think About EDSA?

On Stocktwits, retail sentiment around EDSA stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.

A Stocktwits user highlighted the potential of paridiprubart as a solution for respiratory issues in serious COVID cases.

Another user, however, dismissed the rally as based on a “vague promise” of data in a few weeks.

https://www.stocktwits.com/vanderuk/message/653811537
 

Read More: Tesla Shares Edge Lower As Giant Houston Solar Factory Plans Emerge

For updates and corrections, email newsroom[at]stocktwits[dot]com.